focus -WSS

focus

author：comprehensive 2025-09-03 03:30:54 - browse：4

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： 'Vaccine

WSS

Mystery swirls around US soldier who entered North Korea days ago, officials say

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Sanders wants to replace patents with prizes for drug inventions

Study fuels hope CAR

Wikipedia

focus

focus

Guidelines to prevent youth baseball injuries need more muscle

Elisabeth Bik tackles the widespread issue of research misconduct

Duchenne breakthrough therapy leaves behind pioneering families

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Sports medicine is finally prioritizing gender equality

CDC advisory group OKs chikungunya vaccine

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare isn't yet testing food as medicine

Peter Hotez and the public health issue of online harassment

There’s a way to spot data fakery. All journals should be using it

focus

There’s a way to spot data fakery. All journals should be using it

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Readout Newsletter: Beam, Prozac, "TechBio" and more

Extensive review finds private equity owners jack up cost of care

US jobless claims fall again as labor market continues to flash strength

Are infertility treatments 'essential' during the Covid

entertainment

focus

focus

hotspot